November 23, 2016 - By Hazel Jackson
Christopher Haqq who is the present Chief Medical Officer of Atara Biotherapeutics Inc a few days ago sold 7,068 shares of the Pinksheet-listed Atara Biotherapeutics Inc. The insider transaction has $126,164 US Dollars total value, at an average price per share of $17.9. In the last 30 days, he also sold 1,604 shares with a market value $32,000 USD. Christopher Haqq right now owns 396,105 shares or 1.39% of the Company’s market capitalization (total value of the shares outstanding).
Out of 6 analysts covering Atara Biotherapeutics (NASDAQ:ATRA), 4 rate it a “Buy”, 2 “Sell”, while 0 “Hold”. This means 67% are positive. $80 is the highest target while $8 is the lowest. The $36.50 average target is 99.45% above today’s ($18.3) stock price. Atara Biotherapeutics has been the topic of 13 analyst reports since September 9, 2015 according to StockzIntelligence Inc. The firm has “Sell” rating by Citigroup given on Tuesday, December 15. Goldman Sachs initiated Atara Biotherapeutics Inc (NASDAQ:ATRA) on Wednesday, November 18 with “Neutral” rating. The company was maintained on Tuesday, December 15 by JMP Securities. The firm has “Sell” rating given on Friday, August 19 by Citigroup. As per Friday, September 25, the company rating was initiated by JMP Securities. On Wednesday, September 9 the stock rating was initiated by Canaccord Genuity with “Buy”. The stock of Atara Biotherapeutics Inc (NASDAQ:ATRA) has “Outperform” rating given on Friday, October 9 by William Blair. The firm earned “Sell” rating on Monday, August 22 by Citigroup. On Wednesday, March 9 the stock rating was maintained by JMP Securities with “Market Outperform”. The rating was downgraded by Goldman Sachs on Thursday, September 15 to “Sell”.
Insitutional Activity: The institutional sentiment decreased to 1.48 in Q2 2016. Its down 1.88, from 3.36 in 2016Q1. The ratio is negative, as 6 funds sold all Atara Biotherapeutics Inc shares owned while 8 reduced positions. 7 funds bought stakes while 40 increased positions. They now own 43.46 million shares or 112.65% more from 20.44 million shares in 2016Q1.
Price T Rowe Associate Incorporated Md has invested 0% of its portfolio in Atara Biotherapeutics Inc (NASDAQ:ATRA). The Massachusetts-based State Street Corp has invested 0% in Atara Biotherapeutics Inc (NASDAQ:ATRA). The Illinois-based Ubs Asset Mngmt Americas Incorporated has invested 0.03% in Atara Biotherapeutics Inc (NASDAQ:ATRA). has 0% invested in the company for 13,371 shares. Arrowpoint Asset Mngmt Limited Liability Company reported 1.25 million shares or 0.57% of all its holdings. Goldman Sachs Group Inc owns 16,110 shares or 0% of their US portfolio. Blackrock Invest Mngmt Limited Liability Corp accumulated 94,203 shares or 0% of the stock. Neuberger Berman Grp Limited Liability Corporation reported 629,120 shares or 0.02% of all its holdings. The Massachusetts-based Geode Cap Mgmt Ltd Limited Liability Company has invested 0% in Atara Biotherapeutics Inc (NASDAQ:ATRA). Northern Trust Corp holds 0% of its portfolio in Atara Biotherapeutics Inc (NASDAQ:ATRA) for 240,735 shares. Moreover, Great West Life Assurance Can has 0% invested in Atara Biotherapeutics Inc (NASDAQ:ATRA) for 1,654 shares. Baupost Gp Ltd Liability Co Ma holds 1.64% or 5.36 million shares in its portfolio. Proshare Advsr Ltd Liability Co last reported 24,236 shares in the company. Eagle Asset reported 972,592 shares or 0.15% of all its holdings. Bridger Mgmt Ltd Liability Com owns 1.02 million shares or 1.48% of their US portfolio.
Insider Transactions: Since May 25, 2016, the stock had 0 buys, and 17 insider sales for $2.24 million net activity. Haqq Christopher sold $30,041 worth of Atara Biotherapeutics Inc (NASDAQ:ATRA) on Monday, August 15. Soffer Gad sold $27,247 worth of stock or 1,480 shares. $76,608 worth of Atara Biotherapeutics Inc (NASDAQ:ATRA) shares were sold by Ciechanover Isaac E. 2,995 shares were sold by Clark Mitchall G., worth $58,492. $22,910 worth of Atara Biotherapeutics Inc (NASDAQ:ATRA) shares were sold by Gallagher Carol Giltner. $87,325 worth of Atara Biotherapeutics Inc (NASDAQ:ATRA) was sold by MCGRATH JOHN on Tuesday, October 11.
The stock decreased 1.61% or $0.3 during the last trading session, hitting $18.3. About 178,415 shares traded hands. Atara Biotherapeutics Inc (NASDAQ:ATRA) has declined 12.82% since April 21, 2016 and is downtrending. It has underperformed by 18.14% the S&P500.
Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $544.24 million. The Company’s segment is the business of developing and commercializing therapeutics. It currently has negative earnings. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.
According to Zacks Investment Research, “Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company’s lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California.”
More recent Atara Biotherapeutics Inc (NASDAQ:ATRA) news were published by: Fool.com which released: “Why Atara Biotherapeutics Inc. Shares Are Getting Mauled Today” on December 14, 2015. Also Marketwatch.com published the news titled: “Atara Biotherapeutics stock price target cut to $16 from $23 at Goldman Sachs” on October 17, 2014. Quotes.Wsj.com‘s news article titled: “News Atara Biotherapeutics Inc.ATRA” with publication date: July 19, 2014 was also an interesting one.
Atara Biotherapeutics, Inc., incorporated on August 22, 2012, is a clinical-stage biopharmaceutical company. The Firm is focused on developing therapies for patients with severe and life-threatening diseases. The Company’s segment is the business of developing and commercializing therapeutics. The Firm has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics. The Company’s T-cell product candidates arise from a platform technology designed to produce off-the-shelf, partially human leukocyte antigen (HLA) matched cellular therapeutics utilizing cytotoxic T lymphocytes (CTLs). The Company’s T-cell product candidates target viral or cancer-specific antigens, and are designed to harness the body’s immune system to counteract specific viral infections and cancers. The Company’s T-cell product candidates include Epstein Barr Virus (EBV)-CTL, which is in Phase II clinical trials for malignancies associated with EBV, including EBV-associated post-transplant lymphoproliferative disorders (EBV-PTLD); cytomegalovirus (CMV)-CTL, which is in Phase II clinical trials for CMV, and Wilms Tumor 1 (WT1)-CTL, which targets cancers expressing the antigen WT1 and is in Phase I clinical trials.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.